Cytokine-induced killer cell
immunotherapy is an ideal candidate for adoptive cell transfer
therapy. However, therapeutic approaches to enhance the anti-
tumor activity of cytokine-induced killer cells remain to be explored. Here, we described the successful development of a novel antibody-
chemokine fusion
protein containing the anti-human
Endoglin antibody in the
single-chain variable fragment format and human
interferon-gamma-induced
protein 10 (hENG scFv/hIP-10). Its anti-
Endoglin immunoreactivity and chemotactic activity against the cytokine-induced killer cells were characterized in vitro. To evaluate the anti-
tumor effect in vivo, cytokine-induced killer cells were intravenously injected into human
hepatocellular carcinoma-bearing nude mice, together with intratumoral administration of the fusion
protein hENG scFv/hIP-10 as an enhancer. The
tumor volume and survival time of the mice were monitored, whilst the
tumor-infiltrating cytokine-induced killer cells, serum levels of
interferon-gamma,
tumor cell proliferation, apoptosis, and angiogenesis were measured. The results demonstrated that hENG scFv/hIP-10 and cytokine-induced killer cells synergistically inhibited
tumor growth and prolonged survival of
tumor-bearing mice. Moreover, the number of
tumor-infiltrating cytokine-induced killer cells, serum levels of
interferon-gamma, and
tumor cell apoptosis were increased, accompanied with decreased
tumor proliferation and angiogenesis. Thus, our study suggests that hENG scFv/hIP-10 could enhance the anti-
tumor activity of cytokine-induced killer cells against human
hepatocellular carcinoma.